Intraperitoneal Cis-Platinum/Intravenous Cyclophosphamide Versus Intravenous Cis-Platinum/ Intravenous Cyclophosphamide in Patients with Non-Measurable (Optimal) Disease Stage III Ovarian Cancer

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment.

D Heddens;DS Alberts;EV Hannigan;SD Williams;D Garcia;DJ Roe;J Bell;RD Alvarez Gynecologic Oncology 86:239-243

Phase III study of IP cisplatin plus IV cyclophosphamide vs IV cisplatin plus IV cyclophosphamide in optimal disease stage III ovarian cancer: An Intergroup study 0051 (SWOG-GOG-ECOG).

DS Alberts;PY Liu;EV Hannigan;R O'Toole;SD Williams;J Young;EW Franklin;D Clarke-Pearson;VK Malviya;B DuBeshter;W Hoskins;M Adelson;RD Alvarez;S Vogel;J O'Sullivan;DJ Garcia;D Sparks;ML Rothenberg Society of Gynecologic Oncologists Abstract Book (#1):40

Intraperitoneal cislatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

DS Alberts;PY Liu;EV Hannigan;R O'Toole;SD Williams;JA Young;EW Franklin;DL Clarke-Pearson;VK Malviya;B DuBeshter;MD Adelson;WJ Hoskins New England Journal of Medicine 335(26):1950-1955

Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (pts) with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG Intergroup Study (INT-0051)

DS Alberts;PY Liu;EV Hannigan;R O'Toole;SD Williams;J Young;EW Franklin;D Clarke-Pearson;VK Malviya;S DuBeshter;W Hoskins;M Adelson;RD Alvarez;S Vogel;J O'Sullivan;DJ Garcia;D Sparks;ML Rothenberg ASCO 14:273(#760)